Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's lymphoma study group

Blood

Volumn 92, Issue 12, 1998, Pages 4560-4567

  Tesch, H ^b   Diehl, V ^a   Lathan, B ^b   Hasenclever, D ^b   Sieber, M ^b   Ruffer U ^b   Engert, A ^b   Franklin, J ^b   Pfreundschuh, M ^b   Schalk, K P ^b   Schwieder, G ^b   Wulf, G ^b   Dolken G ^b   Worst, P ^b   Koch, P ^b   Schmitz, N ^b   Bruntsch, U ^b   Tirier, C ^b   Muller U ^b   Loeffler, M ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 17444408871     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.12.4560     Document Type: Article

References (28)

1. De Vita V, Hubbard SM: Hodgkin's disease. N Engl J Med 328:560, 1993
2. DeVita VT, Simon RM, Hubbard SM, Young RS, Berard CW, Moxley JH, Frei E, Carbone PP, Canellos GP: Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587, 1980
3. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 204:739, 1986
4. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992
5. Connors JM, Klimo P, Adams G, Bums BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B: Treatment of advanced Hodgkin's disease with chemotherapy: A comparison of MOPP/ABV hybrid with alternating courses of MOPP and ABVD. A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:1638, 1997
6. Duggan D, Petroni G, Johnson J, Hanson K, Glick J, Connors JM, Cherny R, Barcos M, Peterson BA: MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). ASCO Proc 16:12a, 1997
7. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585, 1980
8. Carde P, MacKintosh FR, Rosenberg SA: A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1:146, 1983
9. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295, 1986
10. Hasenclever D, Loeffler M, Diehl V: Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 7:95, 1996 (suppl 4)
11. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H: BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8:143, 1997
12. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925, 1989
13. Hasenclever D, Brosteanu O, Loeffler M: Design of dose-finding studies to intensify established first or second line chemotherapies using growth factors. Proc Int Soc Clin Biostat 1993 (abstr A57)
14. Clark SC, Kamen R: The human hematopoietic colony-stimulating factors. Science 236:1229 1987
15. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropinia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325:164, 1991
16. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430, 1992
17. Neidhart J, Mangalik A, Kohler W, Stidley C, Saiki J, Duncan P, Souza L, Downing M: Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 11:1685, 1989
18. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG: Received dose-intensity: A randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 12:77, 1994
19. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S: Etoposide (VP-16-213): Current status of an active anticancer drug. N Engl J Med 312:692, 1985
20. Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, Richards JDM: Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 81:197, 1992
21. Kessinger A, Bierman PJ, Vose JM, Armitage JO: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous perpheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 77:2322, 1991
22. Henry-Amar M, Joly F: Late complications after Hodgkin's disease. Ann Oncol 7:115, 1996 (suppl 4)
23. Pui C-H, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Pharm D, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist WM: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682,1991
24. Wirnick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia. J Clin Oncol 11:209, 1993
25. Kreuser ED, Felsenberg D, Behles C, Seibt-Jung H, Mielcarek M, Diehl V, Dahmen E, Thiel E: Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 3:S105, 1992 (suppl 4)
26. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P for the International Database on Hodgkin's Disease Overview Study Group: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 16:818, 1998
27. Aisenberg AC, Martino R, Nomdedeu J, Brunet I, Canellos GP: MOPP, ABVD or both to treat Hodgkin's disease (letter). N Engl J Med 328:1045, 1993
28. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080, 1995